Valneva SE
PAR:VLA
Valneva SE
Valneva SE is a biotech company. The company is headquartered in Saint-Herblain, Pays De La Loire and currently employs 722 full-time employees. The company went IPO on 2007-06-28. The firm's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The firm has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The firm is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
Valneva SE is a biotech company. The company is headquartered in Saint-Herblain, Pays De La Loire and currently employs 722 full-time employees. The company went IPO on 2007-06-28. The firm's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The firm has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The firm is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
Revenue Growth: Q1 total revenues reached almost EUR 50 million, with product sales up 51.2% year-over-year, driven by strong performances in IXIARO and DUKORAL.
Profitability Impact: Gross margins improved significantly, with IXIARO gross margin at 72.6% and DUKORAL at 52.2%, mainly due to better manufacturing performance.
Guidance Maintained: Full-year guidance for product sales and revenues is unchanged; the company expects EUR 170–180 million in product sales and EUR 180–190 million in total revenues.
Cash Position: Cash and cash equivalents stood at EUR 153 million at quarter-end, with operational cash burn reduced by over 70% versus last year.
Pipeline Progress: Key pipeline updates included regulatory advances for IXCHIQ, ongoing Phase III Lyme vaccine study, and new studies initiated for Shigella and Zika candidates.
IXCHIQ Safety Updates: Regulatory authorities issued precautions for use of IXCHIQ in frail elderly following reports of serious adverse events; investigations are ongoing.
Lyme Vaccine Milestones: First major data from the Phase III Lyme vaccine study is expected by year-end, with potential filings planned in 2026.
Analyst Q&A: Management confirmed sales phasing, manufacturing footprint, and gross margin expectations, and addressed recent regulatory changes and order fulfillment.
